Slingshot members are tracking this event:

Teva and Active Biotech discontine high doses of laquinimod in two ongoing studies in multiple sclerosis after the occurrence of cardiovascular events, none of which was fatal, in eight patients; CONCERTO and ARPEGGIO Trials Continue Study

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks




Additional Information

Additional Relevant Details Both trials, CONCERTO and ARPEGGIO, are continuing the lower-dose arms (0.6mg daily), and participants in the trials will be provided with an update to confirm re-consent for participation. The DMC did not identify a cardiovascular signal with the lower dose but recommended long-term monitoring. Through a licensing agreement, Teva has global rights to develop and commercialize laquinimod, a small-molecule entity discovered by Active Biotech.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 04, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Discontinuation, Laquinimod, Multiple Sclerosis, High Dose, Dmc, Ms, Rrms, Ppms